AbbVie stock cuts its Q3 EPS guidance to USD 3.730-3.770
Published on 10/06/2026 at 17:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AbbVie stock was trading at USD 265.96 on the NYSE on October 6, 2026, up 0.08 percent from the prior close, as MarketBeat reported lower third-quarter adjusted EPS guidance of USD 3.730-3.770 on October 6, 2026. The range sits below the USD 3.850 consensus estimate cited in the same update, putting earnings expectations ahead of the October reporting date.
Q3 guidance falls below consensus
The guidance update gives the stock a clear fundamental checkpoint. The lower range reflects acquired in-process research and development and milestone expenses of USD 216 million, while full-year adjusted EPS guidance moved to USD 13.76-13.96 from USD 13.87-14.07, according to MarketBeat.
The latest completed quarter still showed strong operating growth. AbbVie generated USD 16.99 billion in second-quarter 2026 revenue, up 10.2 percent from the prior-year quarter, and adjusted EPS was USD 3.65 versus USD 2.97 a year earlier, according to MarketBeat.
Analysts keep a higher target
Analyst sentiment remains above the latest quote. According to Stock Analysis, 30 analysts give AbbVie a Buy consensus, with an average target of USD 278.86, a low of USD 200 and a high of USD 328. The average target lies 4.85 percent above the USD 265.96 price.
BofA added a separate positive signal on September 29, 2026. The bank raised its target from USD 282 to USD 289 and maintained a Buy rating, according to Markets Insider. The contrast is important: analysts see additional value, while the near-term earnings range has moved lower.
Stock stays below its yearly high
At USD 265.96, AbbVie stock was 1.27 percent below its 52-week high of USD 269.39 and above its 52-week low of USD 190.75 on October 6, 2026. Market capitalization stood at USD 469.9 billion, giving the guidance revision a valuation context without turning it into a recommendation.
AbbVie will publish its third-quarter 2026 results on October 30, 2026, before the market opens, according to PR Newswire. The next investor test is therefore whether revenue growth can offset the lower adjusted EPS range.
USD 265.96 remains the reference
AbbVie stock was last at USD 265.96 on the NYSE on October 6, 2026 at 11:22 a.m. ET, with a daily change of 0.08 percent.
Key facts on AbbVie stock
- Company: AbbVie Inc.
- ISIN: US00287Y1091
- WKN: A1J84E
- Ticker: ABBV
- Trading venue: NYSE
- Price (as of October 6, 2026, 11:22 a.m. ET): USD 265.96
- Market capitalization: USD 469.9 billion (as of October 6, 2026)
- 52-week range: USD 190.75-269.39 (as of October 6, 2026)
- Sector / Industry: Healthcare / Drug Manufacturers - General
Upcoming dates for AbbVie stock
- October 15, 2026: Ex-dividend date
- October 30, 2026: Third-quarter 2026 results
